Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 3/20 | 0.53 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.47 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.41 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.39 |
| ▸ | FEN1 | P39748 | 3/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | CCR8 | P51685 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL19695152 | 0.98 | NNMT (0.51) | NNMTGRM5ASIC3PIK3C3PARP10 | |
| SCHEMBL18068308 | 0.89 | NNMT (0.55) | NNMTGRM5ASIC3PIK3C3PARP10 | |
| SCHEMBL3349695 | 0.77 | NNMT (0.50) | NNMTGRM5ASIC3PIK3C3ADORA2A | |
| SCHEMBL1723715 | 0.76 | NNMT (0.53) | NNMTGRM5ASIC3PIK3C3PARP10 | |
| SCHEMBL21573715 | 0.76 | NNMT (0.57) | NNMTGRM5ASIC3PIK3C3ADORA2A | |
| SCHEMBL10283350 | 0.76 | NNMT (0.53) | NNMTGRM5ASIC3PIK3C3ADORA2A | |
| SCHEMBL8385272 | 0.76 | NNMT (0.53) | NNMTGRM5ASIC3PIK3C3PARP10 | |
| SCHEMBL13154323 | 0.76 | NNMT (0.57) | NNMTGRM5ASIC3PIK3C3ADORA2A | |
| SCHEMBL13004722 | 0.76 | NNMT (0.53) | NNMTGRM5ASIC3PIK3C3ADORA2A | |
| SCHEMBL13538508 | 0.76 | NNMT (0.53) | NNMTGRM5ASIC3PIK3C3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382907-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-11-30 | — | — | US | disclosed |
| US-11807638-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ENLIVEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11767321-B2 | 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases | ENLIVEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230130724-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-04-27 | — | — | US | disclosed |
| EP-3430017-B1 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASES | UNIV CALIFORNIA (US) | 2023-01-25 | — | — | EP | disclosed |
| US-20210371433-A1 | Novel Monocyclic And Bicyclic Ring System Substituted Carbanucleoside Analogues For Use As PRMT5 Inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-02 | — | — | US | disclosed |
| US-20210317111-A1 | NOVEL MEDICAMENT FOR TREATING INFLAMMATORY BOWEL DISEASE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-10-14 | — | — | US | disclosed |
| US-20210032207-A1 | QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-02-04 | — | — | US | disclosed |
| WO-2021013028-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2021-01-28 | — | — | WO | disclosed |
| EP-3459942-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2020-12-30 | — | — | EP | disclosed |
| US-20090253691-A1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253691-A1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-08 | — | — | US | disclosed |
| WO-2009112678-A2 | AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | WO | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | PLEXXIKON INC | 2009-03-19 | — | — | US | disclosed |
| WO-2009016460-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-7312218-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL MYERS SQUIBB CO. (US) | 2007-12-25 | — | — | US | disclosed |
| WO-2007118903-A1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-25 | — | — | WO | disclosed |
| US-20070099922-A1 | SULFONYLAMINOVALEROLACTAMS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | HAN WEI | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371433-A1 | Novel Monocyclic And Bicyclic Ring System Substituted Carbanucleoside Analogues For Use As PRMT5 Inhibitors | PRMT5, PRMT1, PRMT8 | NNMT 63/4885GRM5 185/4885ASIC3 4670/4885 |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | BRAF, RAF1, NRAS | NNMT 1400/4885GRM5 4408/4885ASIC3 2981/4885 |
| US-20090076046-A1 | Compounds modulating c-fms and/or c-kit activity and uses therefor | KIT, FLT3, FLT1 | NNMT 343/4885GRM5 2040/4885ASIC3 3567/4885 |
| US-11807638-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ABL1, ABL2, BCR | NNMT 560/4885GRM5 904/4885ASIC3 4441/4885 |
| US-20070099922-A1 | SULFONYLAMINOVALEROLACTAMS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | TFPI, F12, F5 | NNMT 4318/4885GRM5 4405/4885ASIC3 2042/4885 |
| US-20230382907-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ABL1, ABL2, BCR | NNMT 560/4885GRM5 904/4885ASIC3 4441/4885 |
| US-11767321-B2 | 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases | ABL1, ABL2, BCR | NNMT 560/4885GRM5 904/4885ASIC3 4441/4885 |
| US-20230130724-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ABL1, ABL2, BCR | NNMT 560/4885GRM5 904/4885ASIC3 4441/4885 |
| US-20210032207-A1 | QUINOLONE COMPOUND | HAX1, NQO2, CXCR1 | NNMT 3482/4885GRM5 4283/4885ASIC3 771/4885 |
| US-20090253691-A1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | CHRNA1, CHRNA5, CHRNA3 | NNMT 253/4885GRM5 121/4885ASIC3 735/4885 |
| US-20210317111-A1 | NOVEL MEDICAMENT FOR TREATING INFLAMMATORY BOWEL DISEASE | FABP2, SLC10A2, NFKBIA | NNMT 102/4885GRM5 952/4885ASIC3 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.